The decision by the Food and Drug Administration is expected to add to the demand for a new class of drugs transforming how patients battle obesity.
for treating obesity, opening the door for widespread insurance coverage that could make the sought-after medication affordable for millions of patients.The approval of Zepbound is sure to fuel demand for what is by some measures the most effective obesity drug yet to hit the market, the latest development in a stunning transformation of weight-loss treatments that are captivating a public eager to shed pounds and tantalizing Wall Street.
Lilly earlier this year started production at a manufacturing plant in North Carolina, helping to increase its supply of auto-injectors used to administer Mounjaro. She cautioned that the drug, while ground breaking for obesity treatment, should not be used solely to promote short-term extreme weight loss to the exclusion of healthy eating habits. “It should be used to calm down that hunger noise, and to focus on nutrition and lifestyle things like exercise,” Thiara said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Eli Lilly's Obesity Drug Gets FDA ApprovalThe drug will be marketed as an obesity treatment under the name Zepbound.
Read more »
Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.The drug, which will be sold as Zepbound as an anti-obesity treatment, had previously been cleared by the FDA for the treatment of Type 2 diabetes
Read more »
FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drugThe obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
Read more »
FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drugThe obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
Read more »
FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drugThe obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
Read more »